We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

2 hedge funds and large institutions have $442 invested in Avadel Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 202 closing their positions.

New
Increased
Maintained
Reduced
Closed

75.53% less ownership

Funds ownership: 75.53% → 0% (-76%)

99% less funds holding

Funds holding: 207 → 2 (-205)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less capital invested

Capital invested by funds: $1.6B → $442 (-$1.6B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 202

Holders
2
Holders Change
-205
Holders Change %
-99.03%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
202
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$152M
2
GJL
Gendell Jeffrey L
-$103M
3
WAM
Weiss Asset Management
Massachusetts
-$97.3M
4
TAL
TIG Advisors LLC
New York
-$83.2M
5
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$64.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
51
Yakira Capital Management
Connecticut
– -$5.71M -265,195 Closed
Pictet Asset Management
52
Pictet Asset Management
Switzerland
– -$5.71M -264,974 Closed
AAA
53
Affinity Asset Advisors
New York
– -$5.39M -250,000 Closed
IAM
54
Iridian Asset Management
Connecticut
– -$5.32M -247,086 Closed
VI
55
Versor Investments
New York
– -$5.26M -244,019 Closed
Bank of New York Mellon
56
Bank of New York Mellon
New York
– -$5.19M -240,919 Closed
NPT
57
National Philanthropic Trust
Pennsylvania
– -$4.73M -219,296 Closed
BIP
58
Brandes Investment Partners
California
– -$4.71M -218,425 Closed
MML Investors Services
59
MML Investors Services
Massachusetts
– -$4.69M -217,573 Closed
CCM
60
Cinctive Capital Management
New York
– -$4.31M -200,000 Closed
Swiss National Bank
61
Swiss National Bank
Switzerland
– -$3.72M -172,400 Closed
NICM
62
Neo Ivy Capital Management
New York
– -$3.43M -159,165 Closed
VCM
63
Voleon Capital Management
California
– -$3.31M -153,607 Closed
ACM
64
ADAR1 Capital Management
Texas
– -$3.24M -150,532 Closed
MTCM
65
Mint Tower Capital Management
Netherlands
– -$3.23M -150,000 Closed
Barclays
66
Barclays
United Kingdom
– -$3.21M -148,858 Closed
Man Group
67
Man Group
United Kingdom
– -$3.02M -139,944 Closed
Wells Fargo
68
Wells Fargo
California
– -$3.02M -139,943 Closed
JF
69
Jump Financial
Illinois
– -$2.95M -136,972 Closed
D.E. Shaw & Co
70
D.E. Shaw & Co
New York
– -$2.85M -132,459 Closed
JP Morgan Chase
71
JP Morgan Chase
New York
– -$2.64M -122,476 Closed
YIH
72
Y-Intercept (HK)
Hong Kong
– -$2.6M -120,709 Closed
HF
73
HRT Financial
New York
– -$2.53M -117,259 Closed
Legal & General Group
74
Legal & General Group
United Kingdom
– -$2.47M -114,651 Closed
HWAM
75
Hennion & Walsh Asset Management
New Jersey
– -$2.42M -112,275 Closed
1 2
3
4 5

AVDL Hedge Fund Activity: Q1 2026 in Review

2 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2026, worth a combined $442 — down 100% from $1.6B a quarter earlier.

Sellers outnumbered buyers: 202 funds closed out of AVDL and 0 opened new positions — a net loss of 202 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $152M sold.

  • 2 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2026, down from 207 in Q4 2025.
  • Funds reported $442 of Avadel Pharmaceuticals stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Avadel Pharmaceuticals positions in Q1 2026 and 202 closed out, a net change of -202 holders.
  • The largest Avadel Pharmaceuticals seller in Q1 2026 was BlackRock, an estimated $152M sold.

Based on aggregated 13F filings for Q1 2026.